Alpha Tribe
FeedCompaniesAgentsSubscribe

Filter announcements

  • All
  • Important
  • Results
  • Board Meeting
  • New Orders
  • QIP/Rights/Pref.
  • PPTs
  • JV/Acquisition
  • Insider Trade
  • Dividend/Bonus
  • Credit Ratings
  • Updates
  • Pledging
  • Investor Meet
  • Others

Download our app

Best experience on mobile

Get it on Google PlayDownload on the App Store

Join 5K+ users on Alpha Tribe

Loading...
Venus Remedies Limited logo

Venus Remedies Limited

VENUSREM·Pharmaceuticals

Incorporated in 1989, Venus RemediesLtd is a research based pharmaceutical company and an injectable manufacturer

109Announcements
10-09-2026Last filed
23Last 90 days

What Venus files

  • Others50
  • Important46
  • Board Meeting10
  • Results2
  • Updates1
Showing Important announcements (46)Clear filter
07-09-2026 · 05:33 pm

Venus Remedies has launched a special communication campaign across major social media channels. The initiative aims to inform shareholders about the newly opened special window for re-lodging transfer requests for physical shares, helping investors easily navigate the process and resolve pending paper share transfers.

Read the full announcement→
PDF
18-07-2026 · 05:27 pm

Company uses social media (Instagram, Facebook, LinkedIn, X) to urge shareholders to update KYC details. This proactive communication aims to enhance shareholder data accuracy and regulatory compliance.

Read the full announcement→
PDF
07-07-2026 · 02:46 pm

Venus Remedies announced a special window for shareholders to re-lodge transfer requests for physical shares. This simplifies the process for investors. Details are available on the company's social media platforms.

Read the full announcement→
PDF
16-06-2026 · 12:56 pm

Venus Remedies is using social media (Instagram, Facebook, LinkedIn, X) to prompt shareholders to update their KYC details. This move enhances compliance and improves shareholder communication.

Read the full announcement→
PDF
04-06-2026 · 04:29 pm

Venus Remedies (VENUSREM) renewed crucial R&D recognition, validating its commitment to antimicrobial resistance research. This supports innovative drug development, including USFDA-designated VRP-034, signaling a strong future pipeline.

Read the full announcement→
PDF